Cogent Biosciences adhered to Nasdaq Listing Rule 5635(c)(4) and is developing therapies targeting the KIT D816V mutation.
1 report, 1 independent
Updated Aug 26
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cogent Biosciences adhered to Nasdaq Listing Rule 5635(c)(4) and is developing therapies targeting the KIT D816V mutation.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Cogent Biosciences (United States)
company in Waltham, United States
Nothing else this week.
Coverage
Newest first; wire copies grouped- GlobeNewswireCogent Biosciences Announces Participation in the Citi Biopharma Conference WALTHAM, Mass. and BOULDER, Colo., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnolo